1.
Implications for Reform. New Engl J Med. 2010;362(5):460-5.
2.
Cost-effectiveness to Make Drug Coverage Decisions A Comparison of Britain, Australia, and
Canada. Jama-J Am Med Assoc. 2009;302(13):1437-43.
3.
Japan: a work in progress. J Med Econ. 2020;23(4):317-22.
4.
Weinstein MC, Skinner JA. Comparative Effectiveness and Health Care Spending -
Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using Effectiveness and
Kamae I, Thwaites R, Hamada A, Fernandez JL. Health technology assessment in
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B,
10
Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L, Consortium
11
ANS. AGREE II: advancing guideline development, reporting and evaluation in health care.
12
CMAJ. 2010;182(18):E839-42.
13
5.
14
for the Economic Evaluation of Health Care Programmes. 4th ed. England: Oxford; 2015.
15
6.
16
Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients
17
With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
18
Michael F. Drummond MJS KC, Greg L. Stoddart, George W. Torrance. . Methods
Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA,
JAMA. 2016;316(7):743-53.
48
7.
Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D,
Reporting Standards (CHEERS) statement. Eur J Health Econ. 2013;14(3):367-72.
8.
Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value Health.
2017;20(3):372-8.
9.
Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an Official
Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E, Consensus
Development G. Toward a consensus on the QALY. Value Health. 2009;12 Suppl 1:S31-5.
10.
10
Kopec JA, Willison KD. A comparative review of four preference-weighted
measures of health-related quality of life. J Clin Epidemiol. 2003;56(4):317-25.
11
11.
12
Review of the Empirical Literature. Health Econ. 2015;24(10):1289-301.
13
12.
14
15
16
17
Ryen L, Svensson M. The Willingness to Pay for a Quality Adjusted Life Year: A
Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR.
Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925-30.
13.
Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey
on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost
effectiveness? Health Econ. 2010;19(4):422-37.
49
14.
Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical
interventions. Lancet. 2009;373(9661):423-31.
15.
Schlander M. The use of cost-effectiveness by the National Institute for Health and
Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics.
2008;34(7).
16.
Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J,
Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B,
Sleight P, Franzosi MG, Baigent C, Keech A, de Lemos J, Blazing M, Murphy S, Downs JR,
Gotto A, Clearfield M, Holdaas H, Gordon D, Koren M, Dahlof B, Poulter N, Sever P, Knopp
10
RH, Fellstrom B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E,
11
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V,
12
Sacks F, Moye L, Pfeffer M, Hawkins CM, Kjekshus J, Wedel H, Wikstrand J, Barter P,
13
Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Bloomfield H, Robins S, Armitage J, Parish S,
14
Peto R, Pedersen TR, Ridker PM, Holman R, Meade T, MacMahon S, Marschner I, Shaw J,
15
Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I,
16
Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Cannon
17
C, Murphy S, Armitage J, Bowman L, Parish S, Peto R, Landray M, Rossouw J, Probstfield J,
18
Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert
50
J, Varigos J, White H, Yusuf S, Barnes EH, Keech AC, Kirby A, Marschner IC, Blackwell L,
Emberson J, Herrington WG, Holland LE, Mihaylova B, Reith C, C CTT. Efficacy and safety
of LDL-lowering therapy among men and women: meta-analysis of individual data from 174
000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405.
17.
Kinoshita M YS, Yokote K, Arai H, Iida M, Ishigaki Y, et al. . Japanese
Athrosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular
Disease 1th ed. Tokyo: Athrosclerosis Society; 2017. 13-8 p.
18.
Yang YJ, Lee SH, Kim BS, Cho YK, Cho HJ, Cho KI, Kim SY, Ryu JK, Cho JM,
Park JI, Park JS, Park CG, Chun WJ, Kim MA, Jin DK, Lee N, Kim BJ, Koh KK, Suh J, Lee
10
SH, Lee BK, Oh SJ, Jin HY, Ahn Y, Lees SG, Bae JH, Park WJ, Lee SC, Lee HC, Lee J, Park
11
C, Lee B, Jang Y. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High
12
Cardiovascular Risk. Clin Ther. 2017;39(1):107-17.
13
19.
14
disease prevention: does reality match the hype? Heart. 2017;103(21):1670-9.
15
20.
Hadjiphilippou S, Ray KK. PCSK9 inhibition and atherosclerotic cardiovascular
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA,
16
Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Investigator FSC.
17
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New Engl J Med.
18
2017;376(18):1713-22.
51
21.
Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout
B. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High
Cardiovascular Risk in the United States. Clin Cardiol. 2016;39(6):313-20.
22.
Arrieta A, Page TF, Veledar E, Nasir K. Economic Evaluation of PCSK9 Inhibitors
in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS
One. 2017;12(1):e0169761.
23.
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van
Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab
Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular
10
Disease. JAMA Cardiol. 2017;2(10):1069-78.
11
24.
12
Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F,
Masana L, Bayes-Genis A, Hout BV. Cost-effectiveness of Evolocumab in Patients With High
13
Cardiovascular Risk in Spain. Clin Ther. 2017;39(4):771-86 e3.
14
25.
Korman M, Wisloff T. Modelling the cost-effectiveness of PCSK9 inhibitors vs.
15
ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc
16
Pharmacother. 2018;4(1):15-22.
17
26.
18
Dressel A, Schmidt B, Schmidt N, Laufs U, Fath F, Chapman MJ, Grammer TB,
Marz W. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering
52
cardiovascular events in patients with stable coronary artery disease: Insights from the
Ludwigshafen Risk and Cardiovascular Health cohort. Vascul Pharmacol. 2019;120:106566.
27.
Liang Z, Chen Q, Wei R, Ma C, Zhang X, Chen X, Fang F, Zhao Q. Cost-
Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after
Myocardial Infarction in the Chinese Setting. Front Pharmacol. 2021;12:648244.
28.
Yamaji K, Shiomi H, Morimoto T, Nakatsuma K, Toyota T, Ono K, Furukawa Y,
Nakagawa Y, Kadota K, Ando K, Shirai S, Onodera T, Watanabe H, Natsuaki M, Sakata R,
Hanyu M, Nishiwaki N, Komiya T, Kimura T. Effects of Age and Sex on Clinical Outcomes
After Percutaneous Coronary Intervention Relative to Coronary Artery Bypass Grafting in
10
Patients With Triple-Vessel Coronary Artery Disease. Circulation. 2016;133(19):1878-91.
11
29.
Izuhara M, Ono K, Shiomi H, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S,
12
Tada T, Tazaki J, Horie T, Kuwabara Y, Baba O, Nishino T, Kita T, Kimura T, Investigators
13
CR-KPCRC-. High-density lipoprotein cholesterol levels and cardiovascular outcomes in
14
Japanese patients after percutaneous coronary intervention: a report from the CREDO-Kyoto
15
registry cohort-2. Atherosclerosis. 2015;242(2):632-8.
16
17
18
30.
Nakamura M YH, Ako J, Asai T, Arai H, Ito T, et al. JCS 2018 Guideline on
Revascularization of Stable Coronary Artery Disease. Tokyo: The Japanese Circulation Society;
2018.
53
31.
Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H,
Oishi Y, Ibayashi S, Iida M. Ten year recurrence after first ever stroke in a Japanese
community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2005;76(3):368-72.
32.
Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Nishimiya K, Kikuchi Y, Tsuburaya
R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Age-Specific Trends in the Incidence and In-
Hospital Mortality of Acute Myocardial Infarction Over 30 Years in Japan- Report From the
Miyagi AMI Registry Study. Circ J. 2017;81(4):520-8.
33.
Nakamura M, Tanaka F, Segawa T, Takahashi T, Matsuura Y, Sakai T, Nishiyama O,
Niiyama M, Onoda T, Koshiyama M. Temporal Trends in the Incidence and Clinical Features
10
of Acute Myocardial Infarction in a Japanese Rural Area From 2006 to 2014. Circ J.
11
2017;81(12):1854-61.
12
34.
Shin J, Choi Y, Kim SW, Lee SG, Park EC. Cross-level interaction between
13
individual socioeconomic status and regional deprivation on overall survival after onset of
14
ischemic stroke: National health insurance cohort sample data from 2002 to 2013. J Epidemiol.
15
2017;27(8):381-8.
16
35.
17
Toyota T, Morimoto T, Shiomi H, Ando K, Ono K, Shizuta S, Kato T, Saito N,
Furukawa Y, Nakagawa Y, Horie M, Kimura T, Coho CKPCR. Ad hoc vs. Non-ad hoc
54
Percutaneous Coronary Intervention Strategies in Patients With Stable Coronary Artery Disease.
Circulation Journal. 2017;81(4):458-67.
36.
Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3
Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular
Risk. Am J Cardiol. 2016;117(1):40-7.
37.
https://www.mhlw.go.jp/english/database/db-hw/lifetb14/dl/lifetb14-06.pdf.
38.
Pharmacoeconomics. 2003;21(3):191-200.
10
39.
Secretariat SaIDMs. Abridged Life Tables for Japan 2014 [Available from:
Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke.
Lenzen M, Scholte op Reimer W, Norekval TM, De Geest S, Fridlund B, Heikkila J,
11
Jaarsma T, Martensson J, Moons P, Smith K, Stewart S, Stromberg A, Thompson DR, Wijns W.
12
Pharmacological treatment and perceived health status during 1-year follow up in patients
13
diagnosed with coronary artery disease, but ineligible for revascularization. Results from the
14
Euro Heart Survey on Coronary Revascularization. Eur J Cardiovasc Nurs. 2006;5(2):115-21.
15
16
40.
Kang EJ, Ko SK. A Catalogue of EQ-5D Utility Weights for Chronic Diseases
among Noninstitutionalized Community Residents in Korea. Value in Health. 2009;12:S114-S7.
17
41.
18
Japan. Neurol Med-Chir. 2012;52(4):175-80.
Hattori N, Hirayama T, Katayama Y. Medical Care for Chronic-Phase Stroke in
55
42.
Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J,
Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ, Investigators FT. Cost-
effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass
surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from
the FREEDOM trial. Circulation. 2013;127(7):820-31.
43.
Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K. Japanese
population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life
Res. 2016;25(3):707-19.
44.
Davis KL, Meyers J, Zhao Z, McCollam PL, Murakami M. High-Risk
10
Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population:
11
Prevalence, Cardiovascular Event Rates, and Costs. J Atheroscler Thromb. 2015;22(12):1287-
12
304.
13
45.
14
Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, Ide S, Nanto S.
Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary
15
intervention for ischemic heart disease. Cardiovasc Interv Ther. 2017;32(2):127-36.
16
46.
17
Nanchen D, Gencer B, Muller O, Auer R, Aghlmandi S, Heg D, Klingenberg R,
Raber L, Carballo D, Carballo S, Matter CM, Luscher TF, Windecker S, Mach F, Rodondi N.
56
Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes.
Circulation. 2016;134(10):698-709.
47.
effective for coronary artery disease? Asaio j. 1998;44(5):M666-9.
48.
Kutsumi Y, Tada H, Iwamuro A, Kabuto H. Is low density lipoprotein apheresis
Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B,
Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A,
von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial
hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur
10
Heart J. 2016;37(48):3588-95.
49.
Duell PB, Gidding SS, Andersen RL, Knickelbine T, Anderson L, Gianos E, Shrader
11
P, Kindt I, O'Brien EC, McCann D, Hemphill LC, Ahmed CD, Martin SS, Larry JA, Ahmad ZS,
12
Kullo IJ, Underberg JA, Guyton J, Thompson P, Wilemon K, Roe MT, Rader DJ, Cuchel M,
13
Linton MF, Shapiro MD, Moriarty PM, Knowles JW. Longitudinal low density lipoprotein
14
cholesterol goal achievement and cardiovascular outcomes among adult patients with familial
15
hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019;289:85-93.
16
50.
17
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM,
Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk
57
Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis.
Jama-J Am Med Assoc. 2016;316(12):1289-97.
51.
Im J, Kawada-Watanabe E, Yamaguchi J, Arashi H, Otsuki H, Matsui Y, Sekiguchi
H, Fujii S, Mori F, Ogawa H, Hagiwara N. Baseline low-density lipoprotein cholesterol predicts
the benefit of adding ezetimibe on statin in statin-naive acute coronary syndrome. Sci Rep-Uk.
2021;11(1).
52.
Kao YC, Chen TH, Liu CH, Hwang JS, Hsiao CC, Lin YS, Mao CT, Hung MJ, Li
YR. Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in
comparable intensity for type 2 diabetes with extremely atherosclerotic risks. Sci Rep-Uk.
10
2021;11(1).
11
53.
Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y,
12
Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T,
13
Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y,
14
Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H,
15
Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-
16
Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease
17
(REAL-CAD): A Randomized Superiority Trial. Circulation. 2018;137(19):1997-2009.
58
54.
Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-Year
Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular
Disease. JAMA. 2015;314(2):142-50.
55.
Reckless J, Davies G, Tunceli K, Hu XH, Brudi P. Projected cost-effectiveness of
ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings
from the INFORCE study. Value Health. 2010;13(6):726-34.
56.
Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost-Effectiveness of Statin
Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in
Japanese Patients With Hypercholesterolemia- An Analysis Based on the Japan
10
Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Circ J. 2018;82(4):1076-82.
11
57.
12
Annemans L, Wittrup-Jensen K, Bueno H. A review of international
pharmacoeconomic models assessing the use of aspirin in primary prevention. J Med Econ.
13
2010;13(3):418-27.
14
58.
15
16
Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L. A
health economic evaluation of aspirin in the primary prevention of cardiovascular disease in
Japan. Intern Med. 2007;46(4):157-62.
59
59.
Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG,
Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of
coronary heart disease. N Engl J Med. 2002;346(23):1800-6.
60.
Abdel-Qadir H, Roifman I, Wijeysundera HC. Cost-effectiveness of clopidogrel,
prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-
analytic model. CMAJ Open. 2015;3(4):E438-46.
61.
cilostazol for the secondary prevention of cerebral infarction. Circ J. 2006;70(4):453-8.
62.
10
11
Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S. Pharmacoeconomic analysis of
Singh SM, Wijeysundera HC. Cost-Effectiveness of Novel Oral Anticoagulants for
Stroke Prevention in Non-Valvular Atrial Fibrillation. Curr Cardiol Rep. 2015;17(8):61.
63.
Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ,
12
Tang AC, Feng Wang P, Okumura K. Cost-effectiveness Analysis of Apixaban against
13
Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clin
14
Ther. 2015;37(12):2837-51.
15
64.
16
Cowper PA, DeLong ER, Whellan DJ, Allen LaPointe NM, Califf RM. Economic
effects of beta-blocker therapy in patients with heart failure. Am J Med. 2004;116(2):104-11.
60
65.
Stewart S, McMurray JJ, Hebborn A, Coats AJ, Packer M, Group CS. Carvedilol
reduces the costs of medical care in severe heart failure: an economic analysis of the
COPERNICUS study applied to the United Kingdom. Int J Cardiol. 2005;100(1):143-9.
66.
Inomata T, Izumi T, Kobayashi M. Cost-effectiveness analysis of carvedilol for the
treatment of chronic heart failure in Japan. Circ J. 2004;68(1):35-40.
67.
Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee
TH. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol.
1995;26(4):914-9.
68.
Glick H, Cook J, Kinosian B, Pitt B, Bourassa MG, Pouleur H, Gerth W. Costs and
10
effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of
11
the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail.
12
1995;1(5):371-80.
13
69.
Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in
14
heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril
15
Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
16
Pharmacoeconomics. 1998;14(6):653-69.
61
70.
Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
Multinational economic evaluation of valsartan in patients with chronic heart failure: results
from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004;148(1):122-8.
71.
McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, Vanhaecke
J, van Veldhuisen DJ, Ostergren J, Granger CB, Yusuf S, Pfeffer MA, Swedberg K. Resource
utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality
and morbidity (CHARM) programme. Eur Heart J. 2006;27(12):1447-58.
72.
Imamura T, Kinugawa K, Nitta D, Komuro I. Tolvaptan Reduces Long-Term Total
Medical Expenses and Length of Stay in Aquaporin-Defined Responders. Int Heart J.
10
2016;57(5):593-9.
11
73.
Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JSR, Pepke-Zaba J, Fry-
12
Smith A, Roberts J, Moore D. Clinical and cost-effectiveness of epoprostenol, iloprost,
13
bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed
14
indications: a systematic review and economic evaluation. Health Technol Asses.
15
2009;13(49):1-+.
16
74.
17
18
Igarashi A, Inoue S, Ishi T, Tsutani K, Watanabe H. Comparative Effectiveness of
Oral Medications for Pulmonary Arterial Hypertension Network Meta-Analysis. Int Heart J.
2016;57(4):466-72.
62
75.
Nosrati M, Shahmirzadi NA, Afzali M, Zaboli P, Rouhani H, Hamedifar H, Hajimiri
M. Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension. J Family
Med Prim Care. 2020;9(7):3634-8.
76.
Cohen DJ, Osnabrugge RL, Magnuson EA, Wang K, Li H, Chinnakondepalli K,
Pinto D, Abdallah MS, Vilain KA, Morice MC, Dawkins KD, Kappetein AP, Mohr FW,
Serruys PW, Investigators ST. Cost-effectiveness of percutaneous coronary intervention with
drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery
disease: final results from the Synergy Between Percutaneous Coronary Intervention With
10
TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2014;130(14):1146-57.
77.
Ariyaratne TV, Yap CH, Ademi Z, Rosenfeldt F, Duffy SJ, Billah B, Reid CM. A
11
systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for
12
the treatment of multivessel coronary artery disease in the drug-eluting stent era. Eur Heart J
13
Qual Care Clin Outcomes. 2016;2(4):261-70.
14
78.
15
16
Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost-Effectiveness of
Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart
Disease in Japan. Circ J. 2019;83(7):1498-505.
63
79.
Neyt M, Van Brabandt H, Devos C. The cost-utility of catheter ablation of atrial
fibrillation: a systematic review and critical appraisal of economic evaluations. BMC
Cardiovasc Disord. 2013;13:78.
80.
Kimura T, Igarashi A, Ikeda S, Nakajima K, Kashimura S, Kunitomi A, Katsumata
Y, Nishiyama T, Nishiyama N, Fukumoto K, Tanimoto Y, Aizawa Y, Fukuda K, Takatsuki S.
A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin
and dabigatran based on the CHADS(2) score in Japan. J Cardiol. 2017;69(1-2):89-97.
81.
Kawakami H, Saito M, Kodera S, Fujii A, Nagai T, Uetani T, Tanno S, Oka Y, Ikeda
S, Komuro I, Marwick TH, Yamaguchi O. Cost-Effectiveness of Obstructive Sleep Apnea
10
Screening and Treatment Before Catheter Ablation for Symptomatic Atrial Fibrillation. Circ
11
Rep. 2020;2(9):507-16.
12
82.
Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, Bryant J. Implantable
13
cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation
14
therapy for the treatment of heart failure: systematic review and economic evaluation. Health
15
Technol Assess. 2014;18(56):1-560.
16
83.
17
Kodera S, Kiyosue A, Ando J, Komuro I. Cost effectiveness of transcatheter aortic
valve implantation in patients with aortic stenosis in Japan. J Cardiol. 2018;71(3-4):223-9.
64
84.
Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost-
effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe
aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2020.
85.
Azraai M, Gao L, Ajani AE. Cost-Effectiveness of Transcatheter Aortic Valve
Intervention (TAVI) Compared to Surgical Aortic Valve Replacement (SAVR) in Low- to
Intermediate-Surgical-Risk Patients. Cardiovasc Revasc Med. 2020;21(9):1164-8.
10
86.
Sharples L, Buxton M, Caine N, Cafferty F, Demiris N, Dyer M, Freeman C.
Evaluation of the ventricular assist device programme in the UK. Health Technol Assess.
2006;10(48):1-119, iii-iv.
87.
Seco M, Zhao DF, Byrom MJ, Wilson MK, Vallely MP, Fraser JF, Bannon PG.
11
Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to
12
transplantation: A systematic review. Int J Cardiol. 2017;235:22-32.
13
14
88.
Avancena ALV, Hutton DW, Lee J, Schumacher KR, Si MS, Peng DM. Cost-
effectiveness of implantable ventricular assist devices in older children with stable, inotrope-
15
dependent dilated cardiomyopathy. Pediatr Transplant. 2021.
16
89.
17
Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ.
Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699-703.
65
90.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES,
Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U,
Kastelein JJ, Investigators OLT. Efficacy and safety of alirocumab in reducing lipids and
cardiovascular events. N Engl J Med. 2015;372(16):1489-99.
91.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM,
Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A,
Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM,
Committees OO, Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary
Syndrome. N Engl J Med. 2018;379(22):2097-107.
10
66
...
論文の公開元へ
